Physician profile
John M Morrow
NPI 1609882950
$5,613.06
in general payments reported to CMS, 2019-2025
41 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $302 · 2021: $2,450 · 2022: $750 · 2023: $873 · 2024: $410 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,671.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,233.65 | 2021 | |
| Dexcom, INC. | $490.69 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $404.98 | 2019-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $317.99 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $294.38 | 2019-2022 | |
| Pfizer INC. | $292.45 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $285.93 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $232.91 | 2019-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.14 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $166.94 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $166.91 | 2020-2023 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $153.34 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $136.31 | 2020-2024 | |
| Antares Pharma, INC. | $108.66 | 2021-2023 | Nocdurna, Tlando, Xyosted |
| Novartis Pharmaceuticals Corporation | $99.87 | 2021-2023 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.